Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Hyseq -- Ignore unavailable to you. Want to Upgrade?

To: John Starks who wrote (2)	3/5/1999 1:10:00 AM
From: JF Quinnelly	Read Replies (1) \| Respond to of 11

Thanks for the reply, John. I think I followed it.... I pick up bits and pieces of what this field is about from folks like yourself, but I'd hate to have a pop quiz. So what would HYSQ do with CD39? Would they try to produce it themselves or license it to the pharms? Are you at all familiar with Nanogen? I recently read a DARPA paper on biomolecular computers, Affymetrix and Nanogen were mentioned as participants.

To: John Starks who wrote (2)	3/9/1999 12:13:00 AM
From: John Starks	Respond to of 11

Figured I'd put this post on the Hyseq folder: Thanks for the conference link. Interesting stuff. I think that the "novel hybridization technology" mentioned in the abstract might be Hyseq's. Found this on the Hyseq page (hyseq.com) "In May 1997, Hyseq entered into a collaboration with Chiron in which Hyseq's Gene Discovery program is identifying genes related to solid tumor (cancer) formation. The focus of the collaboration between Hyseq and Chiron is to develop therapeutics, diagnostics and vaccines for solid tumor cancer. Hyseq will receive milestones and royalties on such products. Chiron also has an equity investment in Hyseq. As of December 1998, patent applications on over 6,300 gene discoveries from the collaboration have been filed, validating the approach and commercial power of Hyseq's Gene Discovery program." I am still hopeful about HYSQ and it was good to see that they presented at the conference. If their patent holds up on seq. by hybridization I think it offers them a unique niche to compete with INCY and AFFX. Plus, I think pharmacogenomic applications in the near future will be vast enough to sustain smaller companies. This is especially true with the development of specialized chips based on novel sequences pulled out by the company itself. I have tried to get some answers about the AFFX suit from them but I am still waiting for a response. Not a great sign. I'll post the response when I get it. ------